Literature DB >> 22082040

Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults.

Andrew J Levine1, Janet S Sinsheimer, Robert Bilder, Paul Shapshak, Elyse J Singer.   

Abstract

UNLABELLED: Dopaminergic dysfunction is a putative mechanism underlying HIV-associated neurocognitive disorders. Dopamine transporter (DAT), brain-derived neurotrophic factor (BDNF), and catechol-O-methyltransferase (COMT) have been specifically implicated. We report analyses examining the main effects of functional polymorphisms within dopamine-modulating genes, as well as their interactive effects with disease severity, upon neurocognitive functioning in HIV+ adults.
METHOD: A total of 184 HIV+ adults were included in the analysis. Three polymorphisms were examined within dopamine-modulating genes: COMT val158met, BDNF val66met, and the DAT 3' variable number tandem repeat. Separate hierarchical regression analyses for five neurocognitive domains (working memory, processing speed, learning, memory, motor) were conducted. Predictor variables were age, ethnicity, gender, education, CD4+ T-cell count, current depression, genotype, and an interaction term capturing genotype and disease severity (CD4).
RESULTS: None of the polymorphisms or HIV disease variables significantly improved the hierarchical regression models. Younger age, higher education, and Caucasian ethnicity were almost invariably associated with better functioning across all five cognitive domains. A trend was noted for current depression as a predictor of motor and learning ability.
CONCLUSION: This study did not find evidence to support direct or interactive effects of dopamine-related genes and HIV disease severity on neurocognitive functioning.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082040      PMCID: PMC4361028          DOI: 10.1080/13803395.2011.623118

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  71 in total

1.  Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

2.  Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China.

Authors:  Lucette A Cysique; Scott L Letendre; Christopher Ake; Hua Jin; Donald R Franklin; Saurabh Gupta; Chuan Shi; Xin Yu; Zunyou Wu; Ian S Abramson; Igor Grant; Robert K Heaton
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

3.  HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia.

Authors:  R K Fujimura; K Goodkin; C K Petito; R Douyon; D J Feaster; M Concha; P Shapshak
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-11-01

4.  Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia.

Authors:  Diana P Prata; Andrea Mechelli; Cynthia H Y Fu; Marco Picchioni; Timothea Toulopoulou; Elvira Bramon; Muriel Walshe; Robin M Murray; David A Collier; Philip McGuire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-28       Impact factor: 11.205

Review 5.  Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration.

Authors:  R L Nosheny; I Mocchetti; A Bachis
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

6.  BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization.

Authors:  O Guillin; J Diaz; P Carroll; N Griffon; J C Schwartz; P Sokoloff
Journal:  Nature       Date:  2001-05-03       Impact factor: 49.962

7.  Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine.

Authors:  Venkata S Mattay; Terry E Goldberg; Francesco Fera; Ahmad R Hariri; Alessandro Tessitore; Michael F Egan; Bhaskar Kolachana; Joseph H Callicott; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

Review 8.  Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system.

Authors:  Italo Mocchetti; Rachel L Nosheny; Gianluigi Tanda; Ke Ren; Edwin M Meyer
Journal:  Ann N Y Acad Sci       Date:  2007-12       Impact factor: 5.691

9.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

Review 10.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

View more
  22 in total

Review 1.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

2.  COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV.

Authors:  Rowan Saloner; Maria J Marquine; Erin E Sundermann; Suzi Hong; John Allen McCutchan; Ronald J Ellis; Robert K Heaton; Igor Grant; Mariana Cherner
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

3.  The dopamine-related polymorphisms BDNF, COMT, DRD2, DRD3, and DRD4 are not linked with changes in CSF dopamine levels and frequency of HIV infection.

Authors:  Anne Horn; C Scheller; S du Plessis; R Burger; G Arendt; J Joska; S Sopper; C M Maschke; M Obermann; I W Husstedt; J Hain; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2016-12-01       Impact factor: 3.575

4.  HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations.

Authors:  Michelle M Jacobs; Jacinta Murray; Desiree A Byrd; Yasmin L Hurd; Susan Morgello
Journal:  J Neurovirol       Date:  2013-10       Impact factor: 2.643

Review 5.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

6.  Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity.

Authors:  Stella E Panos; Charles H Hinkin; Elyse J Singer; April D Thames; Sapna M Patel; Janet S Sinsheimer; A C Del Re; Benjamin B Gelman; Susan Morgello; David J Moore; Andrew J Levine
Journal:  Neurobehav HIV Med       Date:  2013-06-19

7.  A family history of substance dependence obscures the group differences in brain function associated with HIV-1 and ART.

Authors:  L O Bauer
Journal:  Drug Alcohol Depend       Date:  2012-06-29       Impact factor: 4.492

Review 8.  Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.

Authors:  Kurt F Hauser; Pamela E Knapp
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

9.  A candidate gene study of intermediate histopathological phenotypes in HIV-associated neurocognitive disorders.

Authors:  Andrew J Levine; Virawudh Soontornniyomkij; Eliezer Masliah; Janet S Sinsheimer; Sarah S Ji; Steve Horvath; Elyse J Singer; Asha Kallianpur; David J Moore
Journal:  J Neurovirol       Date:  2020-05-11       Impact factor: 2.643

10.  Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV.

Authors:  Andrew J Levine; Virawudh Soontornniyomkij; Cristian L Achim; Eliezer Masliah; Benjamin B Gelman; Janet S Sinsheimer; Elyse J Singer; David J Moore
Journal:  J Neurovirol       Date:  2015-12-04       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.